Carterra’s Vega platform expands surface plasmon resonance (SPR) from low‑throughput validation to primary screening, enabling tens of thousands of binding measurements per day, the company says in an Innovation Spotlight. The lead sentence: Vega scales label‑free kinetic and affinity measurements to throughput levels compatible with early discovery screens, potentially reshaping hit triage and off‑target assessment. Carterra argues earlier access to real‑time binding kinetics can improve lead selection and reduce downstream attrition; the platform bridges biophysical precision with discovery volume requirements.